Nintedanib Zentiva (Nintedanib Esylate)

Nintedanib Zentiva is indicated for fibrotic lung disorders and certain cancers where inhibition of multiple tyrosine kinases is therapeutic.

• Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function.
• Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and may delay worsening.
• Non‑small cell lung cancer (in combination with docetaxel): enhances response rates and overall survival in previously treated patients.

• Nintedanib esylate blocks the intracellular kinase activity of several receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR 1‑3), platelet‑derived growth factor receptors (PDGFR‑α/β) and fibroblast growth factor receptors (FGFR 1‑3). Inhibiting these pathways reduces angiogenesis, fibroblast proliferation and extracellular matrix deposition, key processes in fibrosis and tumor growth.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate.
• Nausea: feeling of sickness, may occur early in treatment.
• Vomiting: occasional episodes, usually self‑limiting.
• Decreased appetite: reduced desire to eat.
• Liver enzyme elevation: mild increases in ALT/AST.

Serious or Rare Side Effects

• Severe liver injury: marked elevation of transaminases or hepatitis.
• Cardiovascular events: arterial thromboembolism or myocardial infarction.
• Gastrointestinal perforation: rare but potentially life‑threatening.

Before initiating Nintedanib, clinicians should consider several safety precautions.

• Liver function monitoring: assess baseline ALT/AST and repeat regularly.
• Bleeding risk: avoid in patients with active bleeding or on strong anticoagulants.
• Cardiovascular assessment: evaluate history of ischemic heart disease before use.
• Gastrointestinal health: monitor for severe diarrhea or abdominal pain.
• Pregnancy and lactation: contraindicated in pregnancy (Category D) and not recommended while breastfeeding.
• Store at ambient temperature: keep capsule bottles below 25 °C, protect from moisture and light.

Nintedanib can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.
• P‑glycoprotein inhibitors (e.g., itraconazole): may raise plasma levels.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.
• Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding.
• NSAIDs: increase gastrointestinal adverse events.